Vor Bio Announces The Appointment Of Appoints Navid Z. Khan, Ph.D., As Chief Medical Affairs Officer

Vor Bio, a clinical-stage biotechnology company focused on advancing treatments for autoimmune diseases, announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan brings over 20 years of experience across medical affairs, commercial, and R&D functions, having overseen more than 40 development programs in neurology, immunology, and infectious diseases. 

He has also led seven U.S. and global product launches in rare neurology and immunology indications. Most recently, he served as Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where he directed integrated medical strategy and execution for four launches of VYVGART® and VYVGART Hytrulo®, including two for generalized myasthenia gravis (gMG).

Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio, stated, “Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches. His deep scientific expertise, combined with his ability to connect with patients, physicians, and global stakeholders, will be invaluable as we advance telitacicept and shape our broader autoimmune portfolio.”

Dr. Khan mentioned, “I am thrilled to join Vor Bio at such an exciting time. Vor has the potential to transform the treatment of autoimmune diseases with telitacicept and beyond. I look forward to working with the talented team to build a best-in-class medical affairs function that ensures strong scientific exchange, evidence generation, and meaningful engagement with the patient and physician communities worldwide.”

Earlier in his career, Dr. Khan held senior leadership roles at Akouos Inc. and Sarepta Therapeutics, contributing to the launch of three Duchenne muscular dystrophy therapies — EXONDYS 51®, VYONDYS 53®, and AMONDYS 45® and played a key role in transforming Sarepta’s Medical Affairs organization to support future gene therapy programs. 

He also spent over a decade at EMD Millipore in roles spanning R&D, viral vector and vaccine strategy, and commercial leadership. Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and holds a B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst.